Assistant Professor, Department of Rheumatology, Isfahan University of Medical Sciences, Isfahan
Abstract
Background: About 10% of rheumatoid arthritis patients are seronegative, (rheumatoid factor is negative). These patients may be resistant to conventional anti-rheumatic drugs (DMARDs). Pamidronate is one of the drugs of the bisphosphonate group, which can control bone resorption by effect on osteoclasts. Anti-inflammatory effect of this drug can be exerting by increase monocytes apoptosis, which followed decrease serum level of Interlukin-1 (an inflammatory cytokine). As a result pamidronate can control disease activity.Case Report: In this article, I report two cases of seronegative rheumatoid arthritis that dramatically responds to pamidronate.
Cremers SC, Lodder MC, Den Hartigh J, Ver-meij P, Van Pelt P, Lems WF, et al. Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis. J Rheumatol 2004; 31(9): 1732-7.
Van Offel JF, Schuerwegh AJ, Bridts CH, Bracke PG, Stevens WJ, De Clerck LS. Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid] arthritis treated with low dose prednisolone and methotrexate. Clin Exp Rheumatol 2001; 19(1): 13-20.
Mosayebi G, Rizgar M, Gharagozloo S, Shokri F. Differential expression of rheumatoid fac-tor-associated crossreactive idiotypes in Iranian seropositive and seronegative patients with rheumatoid arthritis. Iran Biomed J 2007; 11(1): 7-13.
Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Breedveld FC. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 1994; 21(11): 2016-20.
Strang P. Analgesic effect of bisphosphonates on bone pain in breast cancer patients. A review article. Acta Oncol 1996; 35(suppl 5): 50–4.
)